Marianne Ellen Pavel



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET (2018) Pavel ME, Rinke A, Baum RP Conference contribution Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR (2018) Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, et al. Journal article Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018) Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al. Journal article Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors (2018) Atanasov G, Tsvetkova , Struecker B, Andreou A, Bahra M, Prasad , Denecke T, et al. Conference contribution Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study (2018) Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Vidal Trueba H, et al. Conference contribution Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution IFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug? (2018) Amoroso V, Pavel ME, Claps M, Roca E, Ravanelli M, Maroldi R, Oberg K, Berruti A Journal article Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms (2018) Fehrenbach U, Fahlenkamp U, Prasad , Pavel ME, Geisel D, Denecke T Conference contribution Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018) Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution